May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients?

Kara, Emre; Inkaya, Ahmet Cagkan; Demirkan, Kutay

Kara, Emre; Inkaya, Ahmet Cagkan; Demirkan, Kutay.

Kara E; Hacettepe University Faculty of Pharmacy, Department of Clinical Pharmacy, Ankara, Turkey. Electronic address: emrekara@hacettepe.edu.tr.
Inkaya AC; Hacettepe University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey.
Demirkan K; Hacettepe University Faculty of Pharmacy, Department of Clinical Pharmacy, Ankara, Turkey.

Int J Antimicrob Agents ; 55(6): 106003, 2020 Jun.

Article in English | MEDLINE | ID: covidwho-181654

Subject(s)

Antiviral Agents/adverse effects; Antiviral Agents/therapeutic use; Cardiovascular Diseases/chemically induced; Coronavirus Infections/drug therapy; Pneumonia, Viral/drug therapy; Betacoronavirus/drug effects; COVID-19; Cardiotoxicity; Humans; Pandemics; Patient Discharge; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Cardiovascular Diseases / Coronavirus Infections Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google